

identify positively botulinum DNA samples in a test of botulinum and non-botulinum clostridia species then to determine the toxin type. The diagnostic testing described by the subject technology requires significantly less time than the current gold standard diagnostic test.

Applications: (1) Universal diagnostic test for *C. botulinum*; (2) Diagnostic test for *C. botulinum* capable of detecting all seven toxin types; (3) Combination diagnostic.

Development Status: Fully developed.
Inventors: Daniel C. Douek (VRC/NIAID) *et al.*

Patent Status: U.S. Provisional Application No. 60/884,539 filed 11 Jan 2007 (HHS Reference No. E-046-2007/0-US-01).

Licensing Status: Available for non-exclusive or exclusive licensing.

Licensing Contact: Susan Ano, Ph.D.; 301/435-5515; anos@mail.nih.gov.

Methods and Compositions for Protecting Cells From Ultrasound-Mediated Cytolysis

Description of Invention: Available for licensing and commercial development are methods for protecting cells from ultrasound-mediated cytolysis. The in vitro exposure of cells to ultrasound and the therapeutic uses of ultrasound (*e.g.*, sonoporation, thrombolysis, HIFU, sonophoresis, acoustic hemostasis) may induce changes in tissue state, including apoptosis and cytolysis, through thermal effects (*e.g.*, hyperthermia), mechanical effects (*e.g.*, acoustic cavitation or through radiation force, acoustic streaming and other ultrasound induced forces), and chemical effects (via sonochemistry or by the activation of solutes by sonoluminescence).

Ultrasound exposure conditions in these biomedical and in biological processes (*e.g.* ultrasound bioreactors) are limited by the need to increase the beneficial effects of ultrasound, while at the same time limiting the detrimental effects, such as apoptosis and cytolysis.

Accordingly, the protecting molecules used to carry out the methods of the invention possess the ability to protect cells against ultrasound mediated cytolysis, without hindering ultrasound induced physical effects that could be utilized to create beneficial effects. The protecting solutes are surface active and possess at least one "carbohydrate unit" as described. The solutes include, but are not limited to: alkyl- β -D-thioglucopyranoside, alkyl- β -D-thiomaltopyranoside, alkyl- β -D-galactopyranoside, alkyl- β -D-thiogalactopyranoside, or alkyl- β -D-maltotriose, hexyl- β -D-glucopyranoside, heptyl- β -D-glucopyranoside, octyl- β -D-

glucopyranoside, nonyl- β -D-glucopyranoside, hexyl- β -D-maltopyranoside, n-octyl- β -D-maltopyranoside, 2-propyl- β -D-thioglucopyranoside, 2-propyl-1-pentyl- β -D-maltopyranoside, methyl-6-O-(N-heptylcarbamoyl)- α -D-glucopyranoside, 3-cyclohexyl-1-propyl- β -D-glucoside, 6-O-methyl-n-heptylcarboxyl- α -D-glucopyranoside.

Inventors: Joe Z. Sostaric (NCI), Peter Riesz (NCI), *et al.*

Publications:

1. Joe Z. Sostaric, Norio Miyoshi, Peter Riesz, William G. DeGraff and James B. Mitchell. n-Alkyl glucopyranosides completely inhibit ultrasound-induced cytolysis. *Free Radic Biol Med.* 2005 Dec 15;39(12):1539-1548.

2. Joe Z. Sostaric, Norio Miyoshi, Peter Riesz, William G. DeGraff and James B. Mitchell. Complete inhibition of ultrasound-induced cytolysis in the presence of inertial cavitation. *AIP Conf Proc.* 2006 May 8;829:39-43.

Patent Status: PCT Application No. PCT/US2005/037912 filed 19 Oct 2005, which published as WO 2006/045050 on 27 Apr 2006; claiming priority to 19 Oct 2004 (HHS Reference No. E-311-2004/0-PCT-02).

Licensing Status: Available for non-exclusive or exclusive licensing.

Licensing Contact: Michael Shmilovich, Esq.; 301/435-5019; shmilovm@mail.nih.gov.

Dated: March 12, 2007.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E7-5426 Filed 3-23-07; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant

applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel, Shared Resource Grant (R24).

Date: April 23, 2007.

Time: 1 p.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Keary A. Cope, PhD, Scientific Review Administrator, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7190, Bethesda, MD 20892-7924, 301-435-2222, copeka@mail.nih.gov.

(Catalogue of Federal Domestic

Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 3.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: March 12, 2007.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07-1450 Filed 3-23-07; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel, Lung Disease Research Project.

Date: April 12, 2007.

Time: 2:30 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).